10-Q: CG Oncology Reports Strong Phase 3 Data, Boosts Manufacturing

CG Oncology announced positive 24-month Phase 3 clinical trial results for cretostimogene in bladder cancer and acquired Biovire to enhance manufacturing capabilities, despite increased net losses.

Summary

• Reported positive topline 24-month data from the BOND-003 Phase 3 clinical trial for cretostimogene in high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS), showing a 41.8% complete response rate.
• Initiated a Biologics License Application (BLA) submission to the U.S. FDA in the fourth quarter of 2025 for cretostimogene based on the BOND-003 trial results.
• Acquired Biovire, Inc., a contract manufacturing organization, on July 20, 2025, to secure clinical supply of cretostimogene, recognizing $12.8 million in goodwill.
• Net loss for the nine months ended September 30, 2025, increased to $119.7 million, compared to $56.2 million for the same period in 2024.
• Research and development expenses rose to $86.7 million for the nine months ended September 30, 2025, up from $55.3 million in the prior year.
• General and administrative expenses increased to $55.5 million for the nine months ended September 30, 2025, from $22.0 million in the previous year.
• Cash, cash equivalents, and marketable securities totaled $680.3 million as of September 30, 2025.
• Successfully defended against a lawsuit from ANI Pharmaceuticals, Inc., with a jury rejecting all claims for unjust enrichment damages on July 29, 2025, meaning no future royalty payments are owed.
• Completed an at-the-market (ATM) offering, selling 1,515,151 shares for net proceeds of $48.7 million during the three months ended September 30, 2025, and an additional 2,343,967 shares for $98.4 million from October 1 to November 13, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to highly encouraging Phase 3 clinical trial results for cretostimogene, successful BLA submission initiation, a strategic acquisition to secure manufacturing, and a favorable outcome in legal proceedings. These operational and clinical successes are significant milestones. However, the company continues to incur substantial and increasing net losses and cash burn, which are expected for a clinical-stage biopharma but still represent a financial challenge requiring future capital raises.

Positives

• Cretostimogene demonstrated strong efficacy and durability in the BOND-003 Phase 3 trial, with a 41.8% 24-month complete response rate and 96.6% of patients free from progression to muscle invasive disease at 24 months.
• The product candidate was generally well-tolerated, with no Grade 3 or greater treatment-related adverse events or deaths reported, and high patient adherence (97.3% completed all expected treatments).
• The BLA submission for cretostimogene was initiated in Q4 2025, indicating significant progress towards potential regulatory approval.
• The acquisition of Biovire, Inc. is a strategic move to secure clinical supply manufacturing, reducing reliance on external contract manufacturing organizations.
• Successfully resolved legal proceedings with ANI Pharmaceuticals, Inc., avoiding a potential 5% royalty on future commercial sales of cretostimogene and any damages.
• Maintained a strong liquidity position with $680.3 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing funding into the first half of 2028.

Negatives

• Net loss significantly increased to $119.7 million for the nine months ended September 30, 2025, compared to $56.2 million in the prior year, reflecting a substantial increase in operating expenses.
• Cash used in operating activities increased to $96.1 million for the nine months ended September 30, 2025, from $58.1 million in the same period of 2024, indicating a higher cash burn rate.
• Research and development expenses increased by $31.4 million, and general and administrative expenses increased by $33.5 million for the nine months ended September 30, 2025, driven by clinical trial costs, increased headcount, and public company expenses.

Risks

• The company will continue to incur significant costs and expenses related to ongoing operations until successful development, regulatory approval, and market acceptance of cretostimogene.
• Inability to accurately predict the timing or amount of increased expenses or when, or if, the company will achieve or maintain profitability.
• Reliance on third parties for the manufacture, packaging, labeling, storage, and distribution of cretostimogene for clinical testing and potential commercialization.
• Need for substantial additional funding to support continuing operations and growth strategy, with potential inability to raise funds on favorable terms or at all.
• Potential for dilution of ownership interest if additional capital is raised through equity or convertible debt securities.
• Risks associated with the successful development of any product candidate, including future trial design, regulatory requirements, and factors beyond the company's control.

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the foreseeable future, anticipating these losses will increase substantially as it advances cretostimogene towards regulatory approval and potential commercialization, discovers new product candidates, and expands its operations. Existing cash, cash equivalents, and marketable securities are estimated to fund operations into the first half of 2028. Future funding will likely come from equity offerings, debt financings, or collaborations, as significant product revenue is not expected until successful clinical development and regulatory approval.

Management Comments

• We are actively building our commercial operations, marketing, market access, and patient access and field force capabilities in anticipation of potential U.S. Food and Drug Administration (FDA) approval.
• Our efforts are focused on ensuring that we are fully prepared to launch and deliver cretostimogene to patients and healthcare providers, if approved.
• The 24-month complete response landmark rate of 41.8% for cretostimogene monotherapy reaffirms the best-in-disease durability that we announced at the 2025 AUA Annual Meeting in April 2025.
• We believe cretostimogene, if approved in intermediate-risk NMIBC, has the potential to serve as backbone therapy, thereby alleviating the current need to prioritize treatment recipients and ration administration of BCG given its significant market shortage.

Industry Context

The company operates in the oncology biopharmaceutical sector, specifically targeting bladder cancer, an area with significant unmet medical need, particularly for patients unresponsive to Bacillus Calmette-Gurin (BCG) therapy. The potential for cretostimogene to serve as a backbone therapy in intermediate-risk NMIBC could address the current market shortage of BCG, positioning the company as a key player in providing alternative treatments.

Comparison to Industry Standards

• Cretostimogene's 24-month complete response rate of 41.8% and 96.6% freedom from progression to muscle invasive disease at 24 months in high-risk BCG-unresponsive NMIBC with CIS demonstrates 'best-in-disease durability,' suggesting a highly competitive profile against existing or emerging therapies in this challenging indication.
• The favorable safety profile, with no Grade 3 or greater treatment-related adverse events and high patient adherence, compares favorably to other cancer treatments which often have more severe side effects and lower compliance rates.

Management Changes

Legal Proceedings

• On July 16, 2025, the Superior Court of the State of Delaware granted the company's motion for summary judgment regarding ANI Pharmaceuticals, Inc.'s request for a declaratory judgment that the company owes a royalty on certain net sales of cretostimogene.
• On July 29, 2025, a jury entered a verdict in favor of the company, unanimously rejecting all of ANI's claims for unjust enrichment damages.
• As a result, the company will not owe ANI a future royalty of 5% on commercial sales of cretostimogene, and no damages have been awarded to ANI.

Stakeholder Impact

• **Shareholders:** Positive clinical data and BLA submission could increase long-term value, but ongoing losses and potential future dilution from capital raises pose risks. The successful legal defense against ANI removes a significant potential royalty burden.
• **Patients:** The positive Phase 3 results for cretostimogene offer hope for a new, effective, and well-tolerated treatment option for high-risk BCG-unresponsive NMIBC, addressing a significant unmet medical need.
• **Employees:** Increased headcount and stock-based compensation indicate growth, but the company's long-term profitability remains uncertain.
• **Customers/Partners:** The acquisition of Biovire aims to secure manufacturing supply, potentially improving reliability for clinical and future commercial needs. Existing collaboration partners (Lepu, Kissei) continue their agreements.

Next Steps

• Continue with the Biologics License Application (BLA) submission process for cretostimogene to the U.S. FDA, initiated in Q4 2025.
• Report updated data from BOND-003 Cohort P (exploratory study in high-risk BCG-unresponsive NMIBC with only Ta/T1 disease) in the fourth quarter of 2025.
• Continue ongoing Phase 2 clinical trials (CORE-008 Cohorts A, B, and CX) for cretostimogene in various NMIBC populations.
• Advance pre-launch activities, including building commercial operations, marketing, market access, patient access, and field force capabilities, in anticipation of potential FDA approval.
• Continue to develop and protect the intellectual property portfolio for cretostimogene and any future product candidates.

Key Dates

Recommendation

The company presents a compelling clinical profile for cretostimogene with strong Phase 3 data, initiating a BLA submission, and strategically acquiring manufacturing capabilities. The successful resolution of the ANI lawsuit is also a significant positive, removing a potential future financial burden. However, as a clinical-stage biopharmaceutical company, it continues to incur substantial and increasing net losses and cash burn, which are expected but still represent a high-risk financial profile. While the long-term potential is significant, the stock has already seen considerable appreciation, and further capital raises are anticipated, which could lead to dilution. A 'hold' recommendation acknowledges the strong clinical progress and strategic positioning while recognizing the inherent financial risks and the need for continued execution and future funding before a clear path to profitability emerges.

Keywords

Bladder cancer, cretostimogene, NMIBC, Oncology, Biopharmaceutical, Clinical trial, Phase 3, FDA, BLA submission, Biovire acquisition, Contract manufacturing, Financial results, Liquidity, Capital raise, Stock options, Legal proceedings